ioTech International, Inc. – Trademark Portfolio
Entity Type: 03
ioTech International, Inc. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 4 trademarks are registered and 1 is pending. Notable registered marks include IOGEL, IOMIST, IORINSE, and IOTECH INTERNATIONAL. The owner is based in Boynton Beach, FL.
170 Commerce Rd, Ste 1
Boynton Beach, FL 33426
Showing of trademarks Trademarks
Trademark Classifications
ioTech International, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does ioTech International, Inc. have?
ioTech International, Inc. has 6 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 pending, 1 abandoned.
What trademark classes does ioTech International, Inc. file in?
ioTech International, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are ioTech International, Inc.'s most well-known trademarks?
ioTech International, Inc.'s registered trademark portfolio includes well-known marks such as IOGEL, IOMIST, IORINSE, and IOTECH INTERNATIONAL. These are among 4 currently registered trademarks in the portfolio.
What is ioTech International, Inc.'s trademark registration success rate?
ioTech International, Inc. has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 1 application is pending review.